Since the beginning of the pandemic, everything and its opposite has been said about antihypertensive medications. Used in patients suffering from high blood pressure, these medications were first thought to aggravate the consequences of COVID-19 before being considered as a new therapeutic avenue for the same disease.
As a PhD candidate in pharmaceutical sciences at the faculty of pharmacy and the Institute for Research in Immunology and Cancer in Montréal, I believe it is important to observe the need for rigorous scientific research before disseminating conclusions on such a subject, especially during a health crisis.
Similar reductions in blood pressure were found to be associated with new use of CCB as with new use of ACEI/ARB in non-black people who did not have diabetes, both in those who were aged younger than 55 and those aged 55 and older.
The usual starting dose of losartan potassium tablet is 50 mg once daily. The dosage can be increased to a maximum dose of 100 mg once daily as needed to control blood pressure
The recommended starting dose of valsartan tablets is 80 mg or 160 mg once daily when used as monotherapy in patients who are not volume-depleted.
Widely prescribed cardiovascular drugs, some recently suspected in high death rates of infected patients, now are being studied for potential protection.
In the search for treatments for COVID-19, many researchers are focusing their attention on a specific protein that allows the virus to infect human cells. Called the angiotensin-converting enzyme 2, or ACE2 “receptor,” the protein provides the entry point for the coronavirus to hook into and infect a wide range of human cells. Might this be central in how to treat this disease?
They found that the risk of severe Covid-19 illness and death was reduced for patients with high blood pressure who were taking Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB).
Our analyses found no evidence of a difference in total mortality or cardiovascular outcomes for ARBs as compared with ACE inhibitors, while ARBs caused slightly fewer WDAEs than ACE inhibitors.
The long-running dispute as to the supremacy of these two drug classes should be put to bed once and for all, say the authors of a new review.
NDMA and NDEA are both the byproducts of various industrial processes, including wastewater treatment. The compounds also appear naturally in some foods, such as cured meats and beer. In the case of the ARB drugs, the problem seems to originate with some of the solvents used to manufacture the active pharmaceutical ingredients, according to the FDA.
It created panic for millions of people who take heart medications every day, but experts say the health risk from quitting is much higher.
Accordingly, we should aim at establishing a combination treatment based on ACE inhibitors in patients with cardiovascular co-morbidities (CAD, CHF, post-AMI). Rather, ARB agents may be prescribed to patients who do not tolerate ACE inhibitors.
ACE Inhibitors and ARBS – these abbreviations may not look all that similar or even have any meaning to you as a patient. However, 1 in 3 adults have high blood pressure and are likely on one of these two types of medication even if they do not know it.
ACE inhibitors and angiotensin-receptor blockers have been found to effectively slow progression of kidney disease. It has been theorized that dual blockade of the renin-angiotensin-aldosterone system (RAAS) might prove even more beneficial, but these hopes have not been realized.
ACE Inhibitors (ACEI) •up to 1% incidence
•angioedema is a class effect and is not dose dependent – symptoms can occur any time from a few hours up to 10 years after the initial dose (Winters et al, 2013)
•more common in African Americans and patients on immunosuppressants
•note that angioedema can occur in patients switched to an angiotensin receptor blocker
Beyond blood pressure control, angiotensin receptor blockers reduce common injury mechanisms, decreasing excessive inflammation and protecting endothelial and mitochondrial function, insulin sensitivity, the coagulation cascade, immune responses, cerebrovascular flow, and cognition, properties useful to treat inflammatory, age-related, neurodegenerative, and metabolic disorders of many organs including brain and lung.
Are you taking an ACE Inhibitor drug? Or perhaps one of their near cousin, ARB (Angiotensin Receptor Blocking) drugs?
And did you know they were being phased out?
The results of the clinical studies in Kansas and Minnesota will provide the first concrete information to clarify the real involvement of losartan, and perhaps this type of antihypertensive in general, in the evolution of COVID-19. At the same time, they will also provide the first answers as to whether this antihypertensive drug is taken at risk or, on the contrary, beneficial in the current context.
Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are mainly used to treat high blood pressure (hypertension) and heart failure. They can also reduce the risk of kidney damage in people with diabetes.